Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Visani

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|March 5, 2003
Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studiesGiovanni Barosi, Barosi Giovanni, Michelle Elliott, et al.
British Journal of Haematology|March 5, 2011
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective studyEmilio Iannitto, Fortunato Morabito, Salvatrice Mancuso, et al.
Blood|January 25, 2002
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized studyLuciana Annino, Maria Luce Vegna, Andrea Camera, et al.
Plos One|November 24, 2011
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosisGiuseppe Visani, Maria Rosaria Sapienza, Alessandro Isidori, et al.
Blood|June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myelomaMassimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
The New England Journal of Medicine|May 12, 2021
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell LeukemiaEnrico Tiacci, Luca De Carolis, Edoardo Simonetti, et al.
Hemasphere|September 25, 2023
Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMTFrancesco Saraceni, Myriam Labopin, Anna M Raiola, et al.
Blood|February 5, 2010
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopeniaFrancesco Zaja, Michele Baccarani, Patrizio Mazza, et al.
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Haematologica|July 30, 2016
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patientsFausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|March 5, 2003
Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studiesGiovanni Barosi, Barosi Giovanni, Michelle Elliott, et al.
British Journal of Haematology|March 5, 2011
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective studyEmilio Iannitto, Fortunato Morabito, Salvatrice Mancuso, et al.
Blood|January 25, 2002
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized studyLuciana Annino, Maria Luce Vegna, Andrea Camera, et al.
Plos One|November 24, 2011
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosisGiuseppe Visani, Maria Rosaria Sapienza, Alessandro Isidori, et al.
Blood|June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myelomaMassimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
The New England Journal of Medicine|May 12, 2021
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell LeukemiaEnrico Tiacci, Luca De Carolis, Edoardo Simonetti, et al.
Hemasphere|September 25, 2023
Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMTFrancesco Saraceni, Myriam Labopin, Anna M Raiola, et al.
Blood|February 5, 2010
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopeniaFrancesco Zaja, Michele Baccarani, Patrizio Mazza, et al.
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Haematologica|July 30, 2016
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patientsFausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, et al.
Pageof 11